Cargando...
Current status of biosimilars in the treatment of inflammatory bowel diseases
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden...
Gardado en:
| Publicado en: | Intest Res |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Korean Association for the Study of Intestinal Diseases
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4754516/ https://ncbi.nlm.nih.gov/pubmed/26884730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2016.14.1.15 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|